56 related articles for article (PubMed ID: 38533063)
21. Prognostic Value and Immunological Role of KIFC1 in Hepatocellular Carcinoma.
Li D; Yu T; Han J; Xu X; Wu J; Song W; Liu G; Zhu H; Zeng Z
Front Mol Biosci; 2021; 8():799651. PubMed ID: 35111813
[TBL] [Abstract][Full Text] [Related]
22. The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors.
Zhu H; Hu X; Feng S; Jian Z; Xu X; Gu L; Xiong X
Oxid Med Cell Longev; 2022; 2022():6419695. PubMed ID: 35082969
[TBL] [Abstract][Full Text] [Related]
23. CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment.
Guan X; Wang Y; Sun Y; Zhang C; Ma S; Zhang D; Li D; Jia W
J Inflamm Res; 2021; 14():7315-7329. PubMed ID: 34992419
[TBL] [Abstract][Full Text] [Related]
24. TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment.
Zhu H; Hu X; Gu L; Jian Z; Li L; Hu S; Qiu S; Xiong X
Front Genet; 2021; 12():759953. PubMed ID: 34721547
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
Front Immunol; 2021; 12():685213. PubMed ID: 34539626
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
Hu X; Zhu H; Zhang X; He X; Xu X
Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
[TBL] [Abstract][Full Text] [Related]
27. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Louis DN; Perry A; Wesseling P; Brat DJ; Cree IA; Figarella-Branger D; Hawkins C; Ng HK; Pfister SM; Reifenberger G; Soffietti R; von Deimling A; Ellison DW
Neuro Oncol; 2021 Aug; 23(8):1231-1251. PubMed ID: 34185076
[TBL] [Abstract][Full Text] [Related]
28.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
29. Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients.
Zhao Z; Zhang KN; Wang Q; Li G; Zeng F; Zhang Y; Wu F; Chai R; Wang Z; Zhang C; Zhang W; Bao Z; Jiang T
Genomics Proteomics Bioinformatics; 2021 Feb; 19(1):1-12. PubMed ID: 33662628
[TBL] [Abstract][Full Text] [Related]
30. PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer.
Xiang A; Lin X; Xu L; Chen H; Guo J; Zhou F
Front Mol Biosci; 2020; 7():544895. PubMed ID: 33392251
[TBL] [Abstract][Full Text] [Related]
31. LAG-3: from molecular functions to clinical applications.
Maruhashi T; Sugiura D; Okazaki IM; Okazaki T
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929051
[TBL] [Abstract][Full Text] [Related]
32. Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression.
Liu HJ; Hu HM; Li GZ; Zhang Y; Wu F; Liu X; Wang KY; Zhang CB; Jiang T
Front Cell Dev Biol; 2020; 8():538. PubMed ID: 32733879
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of PCOLCE by TWIST1 promotes metastasis in Osteosarcoma.
Wang S; Zhong L; Li Y; Xiao D; Zhang R; Liao D; Lv D; Wang X; Wang J; Xie X; Chen J; Wu Y; Kang T
Theranostics; 2019; 9(15):4342-4353. PubMed ID: 31285765
[TBL] [Abstract][Full Text] [Related]
34. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
35. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Harris-Bookman S; Mathios D; Martin AM; Xia Y; Kim E; Xu H; Belcaid Z; Polanczyk M; Barberi T; Theodros D; Kim J; Taube JM; Burger PC; Selby M; Taitt C; Korman A; Ye X; Drake CG; Brem H; Pardoll DM; Lim M
Int J Cancer; 2018 Dec; 143(12):3201-3208. PubMed ID: 30248181
[TBL] [Abstract][Full Text] [Related]
36. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Jiang P; Gu S; Pan D; Fu J; Sahu A; Hu X; Li Z; Traugh N; Bu X; Li B; Liu J; Freeman GJ; Brown MA; Wucherpfennig KW; Liu XS
Nat Med; 2018 Oct; 24(10):1550-1558. PubMed ID: 30127393
[TBL] [Abstract][Full Text] [Related]
37. Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study.
Xiong Y; Wang K; Zhou H; Peng L; You W; Fu Z
Cancer Med; 2018 Sep; 7(9):4496-4508. PubMed ID: 30117315
[TBL] [Abstract][Full Text] [Related]
38. Structural Basis for the Acceleration of Procollagen Processing by Procollagen C-Proteinase Enhancer-1.
Pulido D; Sharma U; Vadon-Le Goff S; Hussain SA; Cordes S; Mariano N; Bettler E; Moali C; Aghajari N; Hohenester E; Hulmes DJS
Structure; 2018 Oct; 26(10):1384-1392.e3. PubMed ID: 30078642
[TBL] [Abstract][Full Text] [Related]
39. Current state of immunotherapy for glioblastoma.
Lim M; Xia Y; Bettegowda C; Weller M
Nat Rev Clin Oncol; 2018 Jul; 15(7):422-442. PubMed ID: 29643471
[TBL] [Abstract][Full Text] [Related]
40. Procollagen C-proteinase enhancer 1 (PCPE-1) functions as an anti-angiogenic factor and enhances epithelial recovery in injured cornea.
Massoudi D; Germer CJ; Glisch JM; Greenspan DS
Cell Tissue Res; 2017 Dec; 370(3):461-476. PubMed ID: 28936615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
